key: cord-1014237-rqywhjtx authors: Azhar, Esam I.; Lanini, Simone; Ippolito, Giuseppe; Zumla, Alimuddin title: The Middle East Respiratory Syndrome Coronavirus – A Continuing Risk to Global Health Security date: 2016-12-14 journal: Emerging and Re-emerging Viral Infections DOI: 10.1007/5584_2016_133 sha: fd9f16f393c2c2de4e4b411beb9d29f5c0f590b7 doc_id: 1014237 cord_uid: rqywhjtx Two new zoonotic coronaviruses causing disease in humans (Zumla et al. 2015a; Hui and Zumla 2015; Peiris et al. 2003; Yu et al. 2014) have been the focus of international attention for the past 14 years due to their epidemic potential; (1) The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) (Peiris et al. 2003) first discovered in China in 2001 caused a major global epidemic of the Severe Acute Respiratory Syndrome (SARS). (2) The Middle East respiratory syndrome coronavirus (MERS-CoV) is a new corona virus isolated for the first time in a patients who died of severe lower respiratory tract infection in Jeddah (Saudi Arabia) in June 2012 (Zaki et al. 2012). The disease has been named Middle East Respiratory Syndrome (MERS) and it has remained on the radar of global public health authorities because of recurrent nosocomial and community outbreaks, and its association with severe disease and high mortality rates (Assiri et al. 2013a; Al-Abdallat et al. 2014; Memish et al. 2013a; Oboho et al. 2015; The WHO MERS-CoV Research Group 2013; Cotten et al. 2013a; Assiri et al. 2013b; Memish et al. 2013b; Azhar et al. 2014; Kim et al. 2015; Wang et al. 2015; Hui et al. 2015a). Cases of MERS have been reported from all continents and have been linked with travel to the Middle East (Hui et al. 2015a; WHO 2015c). The World Health Organization (WHO) have held nine meetings of the Emergency Committee (EC) convened by the Director-General under the International Health Regulations (IHR 2005) regarding MERS-CoV (WHO 2015c). There is wishful anticipation in the political and scientific communities that MERS-CoV like SARS-CoV will disappear with time. However it’s been nearly 4 years since the first discovery of MERS-CoV, and MERS cases continue to be reported throughout the year from the Middle East (WHO 2015c). There is a large MERS-CoV camel reservoir, and there is no specific treatment or vaccine (Zumla et al. 2015a). With 10 million people visiting Saudi Arabia every year for Umrah and/or Hajj, the potential risk of global spread is ever present (Memish et al. 2014a; McCloskey et al. 2014; Al-Tawfiq et al. 2014a). Two new zoonotic coronaviruses causing disease in humans Hui and Zumla 2015; Peiris et al. 2003; Yu et al. 2014 ) have been the focus of international attention for the past 14 years due to their epidemic potential; (1) the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) (Peiris et al. 2003) first discovered in China in 2001 which caused a major global epidemic of the Severe Acute Respiratory Syndrome (SARS); and (2) the Middle East respiratory syndrome coronavirus (MERS-CoV) first isolated from a patient who died of severe lower respiratory tract infection in Jeddah (Saudi Arabia) in June 2012 (Zaki et al. 2012 ). The disease has been named Middle East Respiratory Syndrome (MERS) and it has remained on the radar of global public health authorities because of recurrent nosocomial and community outbreaks, and its association with severe disease and high mortality rates ; There is wishful anticipation in the political and scientific communities that MERS-CoV like SARS-CoV will disappear with time. However it's been nearly 4 years since the first discovery of MERS-CoV, and MERS cases continue to be reported throughout the year from the Middle East (WHO 2015c). There is a large MERS-CoV camel reservoir, and there is no specific treatment or vaccine ). With 10 million people visiting Saudi Arabia every year for Umrah and/or Hajj, the potential risk of global spread is ever present McCloskey et al. 2014; Al-Tawfiq et al. 2014a ). This chapter gives a succinct overview of MERS-CoV epidemiology, clinical features, and highlights the knowledge gaps and its epidemic risk potential. Several studies have sought to ascertain the natural reservoir of MERS-CoV. Studies on bat feces from Middle East, Africa and several European countries have reported CoV in Nycteris and Pipistrellus bats (Annan et al. 2013; Memish et al. 2013c) . From Saudi Arabia, over a thousand bat samples were tested and only one fragment of MERS-CoV was found in one Taphozous bat which was related to MERS-CoV isolated from humans (Memish et al. 2013c) . Several studies have subsequently indicated that MERS-CoV is a zoonotic virus and human infections have been associated with direct or indirect contact with infected dromedary camels (Reusken et al. 2013 Haagmans et al. 2014; Hemida et al. 2014; Meyer et al. 2014; Muller et al. 2014; Gossner et al. 2016 camels. The apparent rarity of MERS-CoV transmission from primary MERS cases apart from hospital settings indicates that the transmission potential and infectivity of such cases is low. The occasional sporadic occurrence of MERS-CoV infection in MERS cases who have any reported animal contact or exposure to MERS cases may be explained by low level infectivity of sub-clinical or asymptomatic cases of MERS-CoV infection (Lessler et al. 2016 ). The sporadic nature of MERS-CoV infection with new cases or clusters distributed over a wide geographic area and rather heterogeneous social settings, represents a significant issue for designing and for implementing solid prospective studies. Thus, the main questions about the epidemiology, source of infection, natural history of the disease, the transmission patterns and pathogenesis remain largely unanswered, as yet . Furthermore, the appearance of MERS-CoV, in human populations soon after the SARS-CoV pandemic emphasizes the importance of a One Health approach (Rabozzi et al. 2012 ) to surveillance of zoonotic infections through integration of human, animal, and environmental health programs. Strengthening surveillance and laboratory networks, as well as training of an effective surveillance workforce is required and needs commitment by all stakeholders, particularly Health Authorities in Middle Eastern Countries. There have been several reviews on the clinical aspects of MERS-CoV ( . MERS presents as a clinical spectrum from the asymptomatic, mild, moderate to severe fulminant multisystem disease. There is limited data on pathogenesis due to lack of autopsy or histological studies. MERS-CoV is known to bind to dipeptidyl peptidase 4 (DPP4) receptors (Lu et al. 2013 ) that are widespread in the body but are primarily located in the lower respiratory tract and thus a typical case of MERS presents with fever, cough, and/or shortness of breath and pneumonia (detailed in Table 1 ). Severe illness can occur in both immunocompetent and immunocompromised host. In general Laboratory confirmation of MERS-CoV infection can be obtained by: (a) MERS-CoV specific nucleic acid amplification test (NAAT) with up to two separate targets and/or sequencing; or (b) virus isolation in tissue culture; or (c) serology on serum tested in a WHO collaborating center with established testing methods. Real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) is used ISARIC and Public Health 2014; Corman et al. 2012 Corman et al. , 2014 for specimens collected from the respiratory tract of suspected cases. CDC recommends the collection of three specimen types, lower respiratory, upper respiratory and serum specimens, for testing using the MERS rRT-PCR assay Accurate laboratory molecular diagnostic tests are available (MERS CDC Laboratory testing for MERS-CoV 2016) using highly sensitive and specific Real-time reverse transcription (RT-PCR) assays targeting unique gene regions such as the upE region (gene region upstream to E gene). These assays have been used for viral load quantitation in studies on viral shedding patterns, optimization of treatment and infection control strategies. Serological tests have been developed for surveillance purposes although they require evaluation in field studies . The clinical management of patients with MERS is largely symptomatic and aimed to reduce the risk of most severe complications, such as secondary infections, and to support renal and respiratory function (Reviewed in Zumla et al. 2015a; WHO 2015b, c; Lessler et al. 2016; Rabozzi et al. 2012; ISARIC and Public Health England 2014; CDC 2016) . Seriously ill patients should receive intensive care. Moreover, the implementation of appropriate infection control measures as soon is possible, is critical for preventing spread of the infection especially in hospitals. Whilst a range of treatments (CDC 2016; WHO 2015b; de Wilde et al. 2013; Falzarano et al. 2013a, b; Chan et al. 2013; Omrani et al. 2014; Shalhoub et al. 2015; Zumla et al. 2016 ) may be useful (Table 2) , currently there are no specific treatments for MERS-CoV infections and no controlled randomized clinical trials of any therapeutic have been conducted to date. A whole range of treatments have been used empirically for serious cases of MERS but there is no solid evidence that any of them can improve the clinical outcome. A range of anti-MERS-CoV drugs and host-directed therapies are in the pipeline [61] ), properly designed, randomized, controlled clinical trials are required to be performed. There have been several nosocomial outbreaks of MERS-CoV infection within Saudi Arabia Oboho et al. 2015; Memish et al. 2013b ). The largest nosocomial outbreak outside Saudi Arabia occurred in mid-2015 in the Republic of Korea (Petersen et al. 2015; Hui et al. 2015b; Zumla et al. 2015c; Kim et al. 2016b) where the index case was 68-year-old male from Korea who visited several Middle Eastern countries (Saudi Arabia, UAE, Bahrain and Qatar) and developed symptoms upon return to Korea and due to lack of isolation and patient consulting several hospitals, a major outbreak ensued involving several hospitals. Early recognition of MERS cases and rapid implementation of infection control guidance is necessary to prevent nosocomial outbreaks of MERS-CoV. Implementation of effective infection control measures at the first consideration of the diagnosis of MERS-CoV is crucial for prevention of MERS-CoV outbreaks. The first major nosocomial outbreak of MER-CoV in 2013 occurred at Al-Hasa, Saudi Arabia in four hospitals where 21 cases of hospital acquired MERS-CoV infection were confirmed by sequence analyses . Global public health authorities guidelines (CDC 2016; WHO 2015b) recommend to use, whenever it is possible airborne infection control (Zumla et al. 2015d ). However this observation may reflect the lack of clinical awareness of MERS and that diagnosis and treatment of respiratory tract infections largely remains empiric, without laboratory confirmation. An estimated 10 million visitors from over 184 countries travel to Saudi Arabia to participate in Hajj pilgrimage, the mini-pilgrimage Umrah or during the month of Ramadan, the vast majority come from developing countries ). If MERS-CoV was a major public health risk, 4 years after its first discover one would have expected cases of MERS-CoV infection in pilgrims. There were no cases of MERS reported during the 2012, 2013, 2014 and 2015 among Hajj pilgrimages (Waldron and Doherty 2015; Lessler et al. 2014) . It is possible that like SARS-CoV, MERS-CoV will die out with time. Conversely it is also possible that MERS-CoV will mutate and increase its transmission potential and the risk of MERS-CoV spreading globally remains. Coker and colleagues (Soliman et al. 2015 ) estimated the potential risk of MERS-CoV infection to pilgrims who visit Saudi Arabia from different regions of the world based on the most likely scenario using recent pilgrim numbers for sub-Saharan Africa. They predict that there will be at most ten returning pilgrims each year with MERS-CoV infections. As the recent Ebola Virus Disease epidemic in West Africa illustrates, African and Asian countries are vulnerable to a Korea-like MERS-CoV outbreak (Zumla et al. 2015e) . A recent study published in Science by Sabir and colleagues (Sabir et al. 2016) found that at least five lineages of MERS-CoV are circulating in Saudi Arabian camels. These results suggest that multiple lineages of MERS-CoV have been co-circulating in Saudi Arabia confirming what was suspected before (Cotten et al. 2013b (Cotten et al. , 2014 . This is a pre-requisite for recombination to occur and it is no surprise that Sabir et al. identified at least six recombination events, showing that recombination is frequent in MERS-CoV. Of interest was that one lineage sequenced by Sabir et al (Sabir et al. 2016 ) was associated with the 2015 Riyadh nosocomial outbreak (Balkhy et al. 2016) , and the MERS-CoV sequenced from the Republic of Korean outbreak also had a recombinant origin. It's been suggested that the recombinant lineage originated between December 2013 and June 2014, and has rapidly become the predominant lineage in Saudi Arabian camels since November 2014. MERS-CoV remains a major threat for global health. With recent outbreaks of Ebola virus and Zika virus a coordinated global response is needed to tackle emerging and re-emerging infectious diseases with epidemic potential (Zumla et al. 2015e; Petersen et al. 2016; Memish et al. 2014b) . Meanwhile there are critical knowledge gaps related to MERS-CoV which, require to be filled (The WHO MERS-CoV Research Group 2013; . Jordan MERS-CoV investigation team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description Surveillance for emerging respiratory viruses Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers Human betacoronavirus 2c EMC/2012-related viruses in bats KSA MERS-CoV investigation team. Hospital outbreak of Middle East respiratory syndrome coronavirus Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Evidence for camel-to-human transmission of MERS coronavirus Notes from the field: nosocomial outbreak of Middle East respiratory syndrome in a large tertiary care hospital -Riyadh, Saudi Arabia Middle East Respiratory Syndrome (MERS) Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus The Middle East Respiratory Syndrome Coronavirus -A Continuing Risk to Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group MERScoronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment Deciphering MERS-CoV evolution in dromedary camels Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity epidemiological findings from a retrospective investigation Advancing priority research on the Middle East respiratory syndrome coronavirus Emerging respiratory tract viral infections Spread of MERS to South Korea and China Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients v2 Complete genome sequence of Middle East respiratory syndrome coronavirus KOR/KNIH/ 002_05_2015, isolated in South Korea Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination. Sci Rep MERS-CoV Scenario Modeling Working Group. Estimating potential incidence of MERS-CoV associated with Hajj Pilgrims to Saudi Arabia MERS-CoV Scenario and Modeling Working Group. Estimating the severity and subclinical burden of Middle East respiratory syndrome coronavirus infection in the Kingdom of Saudi Arabia Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread Family cluster of Middle East respiratory syndrome coronavirus infections Middle East respiratory syndrome coronavirus infections in health care workers Middle East respiratory syndrome coronavirus in bats, Saudi Arabia Hajj: infectious disease surveillance and control Mass gatherings medicine: international cooperation and progress Antibodies against MERS coronavirus in dromedary camels MERS coronavirus neutralizing antibodies in camels A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates MERS-CoV outbreak in Jeddah-A link to health care facilities Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection The severe acute respiratory syndrome Taking stock of the first 133 MERS coronavirus cases globally -Is the epidemic changing? Middle East respiratory syndrome-advancing the public health and research agenda on MERS-lessons from the South Korea outbreak Rapid spread of Zika virus in the Americas -implications for public health preparedness for mass Emerging zoonoses: the "one health approach Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study Geographic distribution of MERS coronavirus among dromedary camels Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study Pilgrims and MERS-CoV: what's the risk? State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans Low public health risk of MERS-CoV in people returning from the Hajj Origin and possible genetic recombination of the Middle East respiratory syndrome coronavirus from the first imported case in China: phylogenetics and coalescence analysis Middle East respiratory syndrome coronavirus (MERS-CoV) -update. Disease outbreak news MERS and the dromedary camel trade between Africa and the Middle East. Trop Anim Health Prod Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Infection control and MERS-CoV in health-care workers Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options State of the ART Seminar: Middle East respiratory syndrome. The Lancet Hostdirected therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections Middle East respiratory syndrome in the shadow of Ebola Middle East respiratory syndrome--need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa Be prepared: Europe needs Ebola outbreak consortium Coronaviruses -drug discovery and therapeutic options